Abstract 12080: Potent Anti-hypertensive Actions of Dietary Flaxseed in Patients With Peripheral Arterial Disease in The Flaxpad Trial
Dietary flaxseed can induce cardioprotective effects in animals. On this basis, a patient population with peripheral artery disease (PAD) was selected as ideal to benefit from dietary flaxseed. Hypertension is a major risk factor strongly associated with PAD complications and death. We hypothesized that dietary flaxseed may provide a significant anti-hypertensive action in patients with PAD.The objectives of this study were to examine the effects of dietary flaxseed on systolic (SBP) and diastolic blood pressure (DBP) in patients with PAD. This was a single center, prospective, double blinded, randomized clinical trial (NCT00781950 at clinicaltrials.gov) in 110 patients >40 years old and with PAD (ABI<0.9). Patients received 30g of milled flaxseed (or placebo) each day over 6 months. Plasma fatty acids and enterolignans over 6 months were measured by gas chromatography.No significant adverse events were associated with flaxseed ingestion. The flaxseed group exhibited a two-fold increase in plasma alpha linolenic acid and a ten-fold increase in enterolactone levels (p=0.003) but the placebo group did not change. Body weights of the subjects were not significantly different between the two groups. SBP in the placebo group increased by ∼3 mmHg and DBP remained the same over the experimental period. However, SBP levels were ∼10 mmHg lower (P<0.04) and DBP was ∼8 mmHg lower (P<0.004) in the flax group compared to placebo. In the flaxseed group, patients with a SBP <140 mmHg at baseline did not receive an anti-hypertensive effect but patients who entered the trial with a SBP ≥140 mmHg at baseline obtained a sustained and significant 15 and 7 mmHg reduction in SBP and DBP, respectively, during the six months. This FlaxPAD Trial has identified one of the mostpotent anti-hypertensive effects ever observed by a dietary intervention. This anti- hypertensive action of dietary flaxseed is evident in Stage 1 and 2 hypertensive PAD patients. The change in BP would be predicted to result in a ∼50% and ∼30% decrease in the incidence of strokes and myocardial infarctions, respectively. Dietary flaxseed represents an appealing strategy for treating hypertension in economically disadvantaged populations. Supported by Flax2015, CIHR, ARDI and the St Boniface Hospital Foundation.
- © 2012 by American Heart Association, Inc.